A new kind of antibody developed by Japan’s Astellas Pharma (TYO: 4503) will be considered for approval in the USA under the Priority Review scheme.
Zolbetuximab is a Claudin 18.2-targeted monoclonal antibody, one of a range of candidates under development addressing this protein, which Astellas plans to market in gastric cancer.
Chief executive Naoki Okamura said: “If approved, zolbetuximab would be the first CLDN18.2-targeted therapy available in the USA for these patients.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze